There are currently no approved vaccines or treatments for norovirus infectionCocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by norovirus infections Phase 1b study is expected to start by year-end 2025 BOTHELL, Wash., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that the Company received a Study May Proceed Letter from the U.S. Food and Drug Administration (FDA) to cond ...

RENO, Nev., Sept. 08, 2025 (GLOBE NEWSWIRE) -- GlobalTech Corporation (OTCID: GTLK) (“GlobalTech” or the “Company”), a U.S.-headquartered technology holding company specializing in artificial intelligence (AI), big data, and emerging technologies, today announced the successful closing of a convertible note private placement funding, securing gross proceeds of USD $1.4 million. The Convertible Promissory Notes do not accrue interest unless an event of default thereunder occurs, and are automatically convert ...

Findings accepted for publication in the official journal of the American College of Allergy, Asthma and Immunology About 9 out of every 10 patients experiencing anaphylaxis were effectively treated with a single dose of neffy Results suggest real-world effectiveness of neffy is consistent with that historically reported for epinephrine injection SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a commercial stage biopharmaceutical company dedicated to empowering at-ris ...

SINGAPORE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Genius Group Limited (NYSE American: GNS) (“Genius Group” or the “Company”), a leading AI-powered, Bitcoin-first education group, today announced that it has appointed Saifedean Ammous as an advisor to the Board. Saifedean Ammous is the bestselling author of “The Bitcoin Standard”, a well-respected economist and public speaker who is regularly invited by the financial media to provide his expert opinion on Bitcoin and cryptocurrency. He has featured in major med ...

Bitcoin treasury as of August 31, 2025 valued at $33.8 million or $2.18 per share¹TAMPA, Fla., Sept. 08, 2025 (GLOBE NEWSWIRE) -- LM Funding America, Inc. (NASDAQ: LMFA) (“LM Funding” or the “Company”), a Bitcoin treasury and mining company, today announced its preliminary, unaudited Bitcoin mining and operational update for the month ended August 31, 2025. MetricJuly 2025August 2025 - Bitcoin2 - Mined, net5.95.8<td style="border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid b ...

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to exercise of warrantsWarrants exercisable at a 20% premium to purchase price SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("Belite Bio" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing novel therapeutics targ ...

VANCOUVER, British Columbia, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Refined Energy Corp. (CSE: RUU | OTC: RRUUF | FRA: CWA0) ("Refined” or the "Company") announces that it has signed an amendment with Searchlight Resources Inc. ("Searchlight") on September 5, 2025 (the “Amended Agreement”), to the option agreements dated August 6, 2024 (the “Agreement”), under which the Company has the right to acquire up to an undivided one hundred percent (100%) interest in and to the Milner and Basin Properties (the “Propert ...

Meeting adjourned to September 19, 2025 at 8:30 a.m. Pacific Time Adjournment provides stockholders with more time given changes in Board composition, additional governance change considerations and future potential disclosures Vaxart encourages all stockholders of record on July 29, 2025 who have not yet voted to do so by 11:59 p.m. Eastern Time on September 18, 2025 SOUTH SAN FRANCISCO, Calif., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”) announced today that ...

Company Overview - UroGen Pharma Ltd. is a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers [4] - The company has developed RTGel, a proprietary sustained-release hydrogel-based platform technology aimed at improving therapeutic profiles of existing drugs [4] - UroGen's first commercial product treats low-grade upper tract urothelial cancer, while its second product is the first FDA-approved medication for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer [4] Recent Developments - UroGen announced the grant of inducement restricted stock units (RSUs) to 40 new employees to support the commercialization of its approved products Jelmyto and ZUSDURI™ [1] - A total of up to 67,700 ordinary shares are issuable upon the vesting and settlement of the RSUs, which will vest equally over three years [2] - The RSUs were granted as an inducement material to each employee entering employment with UroGen, in accordance with Nasdaq Listing Rule 5635(c)(4) [3]

Company to present at session titled “Personalizing Sepsis Treatment” TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its sponsorship of the Unite for Sepsis Symposium, taking place September 8 – 9, 2025, in Chicago, Illinois. The Company also announced that Debra Foster, Clinical Consultant at Spectral Medical, will participate in a featured ...